AK006 targets Siglec-6, an inhibitory receptor found on the surface of mast cells

We are testing AK006 in diseases where mast cells are believed to play a role in the disease pathology. AK006 is directed to an extracellular epitope of the Siglec-6 receptor that was identified for its ability to generate strong inhibitory signals to mast cells. Furthermore, AK006 was engineered to have higher cell surface residence time which may increase mast cell inhibition. In addition to inhibition, in preclinical studies AK006 reduces mast cell numbers via antibody-dependent cellular phagocytosis (ADCP) in the presence of activated macrophages.

AK006 Clinical Development

Ongoing and Planned Studies


Healthy Volunteers (Intravenous, IV)

Results Expected Q2’24

Healthy Volunteers (Subcutaneous, SC)

Results Expected Q3’24

Chronic Spontaneous Urticaria (IV)

Results Expected YE’24